# BPC-157 TB-500 references: the cited literature and FDA sources

> BPC-157 TB-500 references — the full cited literature for the Wolverine blend digest, with PMIDs, DOIs, and FDA source URLs for every quantitative and regulatory claim across the site.

Every quantitative finding and every regulatory statement on this site maps to a numbered entry below. Peer-reviewed studies carry PMIDs and DOIs; regulatory facts cite FDA pages directly.

## How to read this list

This is the [full reference list with PMIDs and DOIs](/references) for the BPC-157 TB-500 digest. Entries 1-9 are the peer-reviewed mechanism, efficacy, identity, and review literature for the two constituents; entries 10-12 are the FDA primary sources behind the regulatory and access statements. Where a peptide finding is attributed to "TB-500," the underlying source frequently studied full-length Thymosin Beta-4 — that distinction is preserved in the citations and throughout the site.

## References

[1] Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. https://pubmed.ncbi.nlm.nih.gov/14554208/
[2] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
[3] Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. https://pubmed.ncbi.nlm.nih.gov/15329672/
[4] Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. https://pubmed.ncbi.nlm.nih.gov/22074294/
[5] Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. https://pubmed.ncbi.nlm.nih.gov/22962027/
[6] Ho ENM, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. https://pubmed.ncbi.nlm.nih.gov/23084823/
[7] Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. (36 studies, 35 preclinical and 1 human; 'shows promise' from level IV-V evidence; 'no clinical safety data were found'; no TB-500 or combination data.) https://pubmed.ncbi.nlm.nih.gov/40756949/
[8] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/
[9] Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. (Human data limited to three pilot studies; BPC-157 should be considered investigational; reports the sub-30-minute animal elimination half-life and non-regulated availability.) https://pubmed.ncbi.nlm.nih.gov/40789979/
[10] U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. (Category 2 entries for 'BPC-157 (free base)' / 'BPC-157 acetate' and 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500,' effective with the September 29, 2023 update; verified 2026-05-29.) https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
[11] U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. (Category 1/Category 2 definitions; the 503A/503B framework; the January 7, 2025 change to categorization of newly nominated substances; verified 2026-05-29.) https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
[12] U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. (Public calendar listing BPC-157 and TB-500, with KPV and MOTS-c, as bulk drug substances 'being considered for inclusion on the 503A Bulks List' — a scheduled discussion, not a decision; verified 2026-05-29.) https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

---

Two constituent channels read off one console — BPC-157 traced to its studies and TB-500 to its own, the repair-signal node where they converge left dark because no combination trial exists, and the FDA 503A and WADA marks posted before anything else; no clinic behind the readout and nothing here dispensed.